Scope Fluidics SA (SCP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scope Fluidics SA (SCP) has a cash flow conversion efficiency ratio of -0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.75 Million ≈ $-3.23 Million USD) by net assets (zł115.43 Million ≈ $31.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Scope Fluidics SA market cap and net worth for the company's overall valuation and market capitalisation.
Scope Fluidics SA - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Scope Fluidics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scope Fluidics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scope Fluidics SA ranked by their cash flow conversion efficiency. Explore SCP cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CGRE AG
XETRA:CGX
|
N/A |
|
Evergreen Max Cash Capital Berhad
KLSE:0286
|
-0.215x |
|
RiTdisplay Corp
TW:8104
|
0.022x |
|
Euroapi SAS
PA:EAPI
|
-0.091x |
|
Chernan Metal Industrial
TWO:3631
|
0.004x |
|
ANDRADA MINING LTD.
F:9IA
|
N/A |
|
Positivo Tecnologia S.A
SA:POSI3
|
0.073x |
|
Beazley plc
LSE:BEZ
|
0.050x |
Annual Cash Flow Conversion Efficiency for Scope Fluidics SA (2015–2024)
The table below shows the annual cash flow conversion efficiency of Scope Fluidics SA from 2015 to 2024. View SCP stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł146.35 Million ≈ $40.28 Million |
zł-25.10 Million ≈ $-6.91 Million |
-0.172x | +27.15% |
| 2023-12-31 | zł80.93 Million ≈ $22.27 Million |
zł-19.06 Million ≈ $-5.24 Million |
-0.235x | -178.45% |
| 2022-12-31 | zł332.97 Million ≈ $91.64 Million |
zł-28.16 Million ≈ $-7.75 Million |
-0.085x | +94.44% |
| 2021-12-31 | zł14.58 Million ≈ $4.01 Million |
zł-22.19 Million ≈ $-6.11 Million |
-1.522x | -215.52% |
| 2020-12-31 | zł33.09 Million ≈ $9.11 Million |
zł-15.96 Million ≈ $-4.39 Million |
-0.482x | +6.93% |
| 2019-12-31 | zł20.22 Million ≈ $5.56 Million |
zł-10.48 Million ≈ $-2.88 Million |
-0.518x | -23.38% |
| 2018-12-31 | zł12.81 Million ≈ $3.52 Million |
zł-5.38 Million ≈ $-1.48 Million |
-0.420x | -43.76% |
| 2017-12-31 | zł16.88 Million ≈ $4.64 Million |
zł-4.93 Million ≈ $-1.36 Million |
-0.292x | +57.84% |
| 2016-12-31 | zł5.58 Million ≈ $1.53 Million |
zł-3.87 Million ≈ $-1.06 Million |
-0.693x | -966.74% |
| 2015-12-31 | zł6.70 Million ≈ $1.84 Million |
zł535.69K ≈ $147.43K |
0.080x | -- |
About Scope Fluidics SA
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.